Abivax S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABVX.PA research report →
About the company
Abivax S. A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer.
- CEO
- Marc de Garidel
- IPO
- 2015
- Employees
- 69
- HQ
- Paris, FR
Price Chart
- Market Cap
- $6.44B
- P/E
- -16.71
- P/S
- 0.00
- P/B
- 12.33
- EV/EBITDA
- -23.91
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -165.19%
- ROIC
- -45.51%
- Revenue
- $0 · -100.00%
- Net Income
- $-336,102,000 · -90.70%
- EPS
- $-4.83 · -72.50%
- Op Income
- $-250,625,000
- FCF YoY
- -4.86%
- 52W High
- $132.00
- 52W Low
- $5.63
- 50D MA
- $97.06
- 200D MA
- $96.41
- Beta
- -0.20
- Avg Volume
- 278.52K
Get TickerSpark's AI analysis on ABVX.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ABVX.PA coverage
Recent articles, reports, and earnings notes.
No research on ABVX.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABVX.PA report →Similar companies
Peers in the same neighborhood.